Panbela Therapeutics Statistics
Share Statistics
Panbela Therapeutics has 4.85M
shares outstanding. The number of shares has increased by 39.45%
in one year.
| Shares Outstanding | 4.85M |
| Shares Change (YoY) | 39.45% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0.01% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 845 |
| FTD / Avg. Volume | 3.99% |
Short Selling Information
The latest short interest is 106.97K, so undefined% of the outstanding
shares have been sold short.
| Short Interest | 106.97K |
| Short % of Shares Out | n/a |
| Short % of Float | 2.2% |
| Short Ratio (days to cover) | 0.07 |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | -0.07 |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Panbela Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.25,
with a Debt / Equity ratio of -1.1.
| Current Ratio | 0.25 |
| Quick Ratio | 0.25 |
| Debt / Equity | -1.1 |
| Debt / EBITDA | -0.1 |
| Debt / FCF | -0.21 |
| Interest Coverage | 161.81 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-3,609,000 |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -186K |
| Effective Tax Rate | 0.73% |
Stock Price Statistics
The stock price has increased by -44.15% in the
last 52 weeks. The beta is 1.25, so Panbela Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.25 |
| 52-Week Price Change | -44.15% |
| 50-Day Moving Average | 0.36 |
| 200-Day Moving Average | 0.36 |
| Relative Strength Index (RSI) | 43.87 |
| Average Volume (20 Days) | 21,183 |
Income Statement
| Revenue | n/a |
| Gross Profit | -25.65M |
| Operating Income | -51.29M |
| Net Income | -25.26M |
| EBITDA | -51.29M |
| EBIT | -25.77M |
| Earnings Per Share (EPS) | -232429.55 |
Full Income StatementBalance Sheet
The company has 2.58M in cash and 5.19M in
debt, giving a net cash position of -2.62M.
| Cash & Cash Equivalents | 2.58M |
| Total Debt | 5.19M |
| Net Cash | -2.62M |
| Retained Earnings | -125.5M |
| Total Assets | 5.17M |
| Working Capital | -14.97M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -25.25M
and capital expenditures 0, giving a free cash flow of -25.25M.
| Operating Cash Flow | -25.25M |
| Capital Expenditures | n/a |
| Free Cash Flow | -25.25M |
| FCF Per Share | -232300.74 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
